The company delivered strong cannabis revenue growth, led by a 43% increase in Canada adult-use sales, while Storz & Bickel revenues fell 25%. Gross margin declined to 25% due to product mix and lower high-margin market sales. Operating loss improved on reduced expenses. Adjusted EBITDA loss widened, but free cash flow outflow was significantly reduced.
Consolidated net revenue rose 9% YoY to $72.1M, driven by cannabis segment growth.
Canada adult-use cannabis sales surged 43% YoY to $27.0M.
Gross margin contracted to 25% from 35% due to mix shifts and lower high-margin sales.
Free cash flow outflow decreased 79% YoY to $11.6M.
Management expects continued cannabis sales momentum in Canada and improved supply in European markets in H2 FY2026, with gross margin improvement initiatives underway. Storz & Bickel to launch a new vaporizer in H2 calendar 2025.
Visualization of income flow from segment revenue to net income